Fair Isaac (FICO) & Protagenic Therapeutics (PTIX) Financial Contrast
Fair Isaac (NYSE:FICO) and Protagenic Therapeutics (OTCMKTS:PTIX) are both computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.
Earnings & Valuation
This table compares Fair Isaac and Protagenic Therapeutics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Fair Isaac||$1.03 billion||8.35||$142.41 million||$4.34||68.52|
|Protagenic Therapeutics||N/A||N/A||-$2.56 million||N/A||N/A|
This table compares Fair Isaac and Protagenic Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
84.2% of Fair Isaac shares are owned by institutional investors. 6.1% of Fair Isaac shares are owned by company insiders. Comparatively, 51.1% of Protagenic Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility and Risk
Fair Isaac has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Protagenic Therapeutics has a beta of -7.89, indicating that its stock price is 889% less volatile than the S&P 500.
This is a breakdown of recent ratings and recommmendations for Fair Isaac and Protagenic Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Fair Isaac currently has a consensus price target of $305.00, suggesting a potential upside of 2.56%. Given Fair Isaac’s higher possible upside, research analysts plainly believe Fair Isaac is more favorable than Protagenic Therapeutics.
Fair Isaac beats Protagenic Therapeutics on 9 of the 10 factors compared between the two stocks.
About Fair Isaac
Fair Isaac Corporation develops analytic, software, and data management products and services that enable businesses to automate, enhance, and connect decisions. The company offers analytical solutions, credit scoring, and credit account management products and services to banks, credit reporting agencies, credit card processing agencies, insurers, retailers, healthcare organizations, and public agencies. It operates through three segments: Applications, Scores, and Decision Management Software. The Applications segment offers pre-configured decision management applications designed for various business problems or processes, such as marketing, account origination, customer management, fraud, collection, and insurance claims management, as well as associated professional services. The Scores segment provides business-to-business scoring solutions and services, including myFICO solutions for consumers that give clients access to analytics to be integrated into their transaction streams and decision-making processes, as well as associated professional services. The Decision Management Software segment offers analytic and decision management software tools, as well as associated professional services. The company offers a portfolio of applications, tools, and services in the cloud to clients through its FICO Analytic Cloud, FICO Decision Management Suite, and FICO Decision Management Platform. Fair Isaac Corporation markets its products and services primarily through its direct sales organization; indirect channels; subsidiary sales organizations; and resellers and independent distributors, as well as online. It operates in the United States, the United Kingdom, and internationally. The company was formerly known as Fair Isaac & Company, Inc. and changed its name to Fair Isaac Corporation in July 1992. Fair Isaac Corporation was founded in 1956 and is headquartered in San Jose, California.
About Protagenic Therapeutics
Protagenic Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics to treat central nervous system disorders. Its lead drug candidate is PT00114, which is in clinical proof-of-concept studies for the treatment-resistant depression and/or post-traumatic stress disorder. The company is based in New York, New York.
Receive News & Ratings for Fair Isaac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fair Isaac and related companies with MarketBeat.com's FREE daily email newsletter.